Residency · Residency · Pediatrics
Neonatal Jaundice and Hyperbilirubinemia
Overview
Jaundice is visible in approximately 60% of term and 80% of preterm newborns during the first week of life. While most neonatal jaundice is physiologic and benign, severe unconjugated hyperbilirubinemia carries the risk of kernicterus -- bilirubin-induced neurologic dysfunction resulting in permanent brain injury. The AAP 2022 guidelines updated phototherapy thresholds and emphasize stratification by neurotoxicity risk factors to guide management.
Bilirubin Metabolism
Bilirubin is the end product of heme degradation, primarily from the breakdown of red blood cells. Heme oxygenase converts heme to biliverdin, which is then reduced to unconjugated bilirubin by biliverdin reductase. Unconjugated (indirect) bilirubin is lipid-soluble and circulates bound to albumin in plasma. In the liver, the enzyme UDP-glucuronosyltransferase (UGT1A1) conjugates bilirubin with glucuronic acid, producing conjugated (direct) bilirubin that is water-soluble and excreted in bile into the intestine. Neonates are predisposed to hyperbilirubinemia because they have a high heme load (from higher red blood cell mass and shorter RBC lifespan of 70-90 days versus 120 days in adults) combined with immature hepatic conjugation capacity.
Physiologic vs. Pathologic Jaundice
Physiologic Jaundice
Physiologic jaundice appears after 24 hours of life, peaks at day 3-5 in term infants (day 5-7 in preterm), produces total serum bilirubin (TSB) generally below 15 mg/dL in term infants, and resolves by 1-2 weeks. It results from the combination of immature hepatic conjugation, increased enterohepatic circulation (neonatal intestinal beta-glucuronidase deconjugates bilirubin for reabsorption), and the high rate of bilirubin production inherent to neonatal physiology.
Pathologic Jaundice (Red Flags)
| Feature | Physiologic Jaundice | Pathologic Jaundice |
|---|---|---|
| Onset | After 24 hours of life | Within first 24 hours |
| TSB rise rate | <5 mg/dL/day | >5 mg/dL/day or >0.2 mg/dL/hour |
| Peak TSB (term) | Generally <15 mg/dL | Exceeds age-specific thresholds |
| Duration | Resolves by 1-2 weeks | Persists beyond 2 weeks (term) |
| Direct bilirubin | Normal | >1.0 mg/dL or >20% of TSB |
| Clinical status | Well-appearing | Lethargy, poor feeding, high-pitched cry |
Jaundice is considered pathologic when it appears within the first 24 hours of life, when TSB rises faster than 5 mg/dL per day or 0.2 mg/dL per hour, when TSB exceeds age-specific phototherapy thresholds, when jaundice persists beyond 2 weeks in term infants, when direct (conjugated) bilirubin exceeds 1.0 mg/dL or 20% of TSB, or when it is associated with lethargy, poor feeding, or a high-pitched cry.
Etiologies of Neonatal Hyperbilirubinemia
Increased Production
Conditions that increase bilirubin production include ABO incompatibility (the most common immune hemolytic disease in neonates), Rh isoimmunization, G6PD deficiency (a significant global cause of severe jaundice), hereditary spherocytosis and elliptocytosis, extravascular blood accumulation (cephalohematoma, extensive bruising), polycythemia, and sepsis.
Decreased Conjugation
Reduced conjugation capacity occurs in physiologic immaturity, Gilbert syndrome (benign UGT1A1 polymorphism), Crigler-Najjar syndrome types I and II (severe UGT1A1 deficiency), and hypothyroidism.
Increased Enterohepatic Circulation
Enhanced reabsorption of bilirubin from the intestine occurs in breast milk jaundice (where beta-glucuronidase in breast milk deconjugates bilirubin), breastfeeding jaundice (resulting from inadequate caloric intake and dehydration in the first days of life), and intestinal obstruction (pyloric stenosis, Hirschsprung disease).
Risk Assessment: Bhutani Nomogram
The Bhutani nomogram provides hour-specific risk stratification by plotting TSB against postnatal age. It defines four risk zones: low risk (below the 40th percentile), low-intermediate (40th to 75th percentile), high-intermediate (75th to 95th percentile), and high risk (above the 95th percentile). Transcutaneous bilirubin (TcB) measurement can be used for screening, but TSB is required for treatment decisions at higher levels approaching phototherapy thresholds.
AAP 2022 Updated Guidelines
Neurotoxicity Risk Factors
The 2022 guidelines identify specific neurotoxicity risk factors that lower phototherapy thresholds: gestational age 35-37 6/7 weeks, serum albumin below 3.0 g/dL, isoimmune hemolytic disease (positive direct antiglobulin test), G6PD deficiency, sepsis, and significant clinical instability in the preceding 24 hours.
Phototherapy Thresholds
Treatment thresholds are based on gestational age and the presence of neurotoxicity risk factors. The 2022 thresholds are generally higher than the 2004 guidelines for infants at 38 weeks or greater without risk factors, while maintaining lower thresholds for preterm infants and those with risk factors. For example, a term infant without risk factors would meet phototherapy criteria at approximately 18-20 mg/dL at 48-72 hours of age.
Escalation Thresholds
When TSB continues to rise despite intensive phototherapy and approaches exchange transfusion levels, escalation measures include intravenous fluid supplementation, evaluation for ongoing hemolysis, and preparation for possible exchange transfusion.
Phototherapy
Phototherapy works by converting unconjugated bilirubin to water-soluble photoisomers (primarily lumirubin) that can be excreted in bile and urine without hepatic conjugation. The blue-green light spectrum (460-490 nm) is most effective. Intensive phototherapy requires an irradiance of 30 microwatts/cm2/nm or greater. Maximizing exposed skin surface area and combining overhead lights with fiber-optic pads increases efficacy. TSB is monitored every 4-6 hours during treatment. Phototherapy is discontinued when TSB falls below the treatment threshold (typically 13-14 mg/dL in term infants), with a rebound TSB check performed 12-24 hours later. Side effects include insensible water loss, temperature instability, bronze baby syndrome (in the setting of conjugated hyperbilirubinemia), and the need for retinal shielding.
Exchange Transfusion
Exchange transfusion is indicated when TSB approaches or exceeds the exchange threshold despite intensive phototherapy. A double-volume exchange (160 mL/kg) removes approximately 85% of circulating bilirubin and antibody-coated red blood cells. It is performed via umbilical venous catheter with continuous cardiac monitoring. Risks include electrolyte imbalances (particularly hypocalcemia and hyperkalemia), thrombocytopenia, infection, cardiac arrhythmia, NEC, and death (approximately 0.3%). Intravenous immunoglobulin (IVIG) at 0.5-1 g/kg may reduce the need for exchange transfusion in cases of isoimmune hemolytic disease.
Conjugated (Direct) Hyperbilirubinemia
Direct bilirubin exceeding 1.0 mg/dL is always pathologic and demands prompt investigation. Conjugated hyperbilirubinemia is never treated with phototherapy, which can cause the bronze baby syndrome in this context. The most important surgical cause is biliary atresia, where timely Kasai portoenterostomy (ideally by 30-45 days of life) is essential for outcomes. Other etiologies include choledochal cyst, neonatal hepatitis (idiopathic or viral from CMV or HSV), alpha-1 antitrypsin deficiency, Alagille syndrome, TPN-associated cholestasis, galactosemia, tyrosinemia, and cystic fibrosis. The workup includes fractionated bilirubin, GGT, hepatic ultrasound, HIDA scan (if biliary atresia is suspected), and metabolic and genetic studies.
Screening Approaches
Universal predischarge bilirubin screening (TSB or TcB) is recommended by the AAP. Targeted screening based on risk factors alone misses some cases of significant hyperbilirubinemia. All newborns should have bilirubin checked before discharge or at 24-48 hours. The timing of follow-up after discharge is determined by the risk zone, age at discharge, and presence of risk factors.
<image>A detailed illustration of the Bhutani hour-specific bilirubin nomogram, showing the four risk zones (low, low-intermediate, high-intermediate, high risk) plotted against postnatal age in hours (x-axis) and total serum bilirubin in mg/dL (y-axis), with color-coded zones from green to red. Include sample plotted points showing how clinical decisions are made based on zone placement.</image>
<image>A diagram of bilirubin metabolism from heme breakdown in the reticuloendothelial system through unconjugated bilirubin transport bound to albumin, hepatic conjugation by UGT1A1, biliary excretion, and intestinal processing. Show the enterohepatic circulation loop with beta-glucuronidase deconjugation in the neonatal intestine. Medical biochemistry illustration style with labeled enzymes and pathways.</image>
<image>A photograph-style medical illustration showing a newborn under phototherapy lights, with blue LED panels above and a fiber-optic blanket below, eye shields in place, with an inset molecular diagram showing the photoisomerization of unconjugated bilirubin (4Z,15Z-bilirubin) to the water-soluble lumirubin isomer upon light absorption.</image>
Clinical Pearls
Jaundice in the first 24 hours of life is always pathologic and requires urgent evaluation for hemolytic disease. G6PD deficiency is a frequently missed cause of severe neonatal jaundice and should be considered across all ethnicities, not only those traditionally considered high-risk. Breastfeeding jaundice from inadequate intake occurs in the first week of life, while breast milk jaundice from milk components peaks at 2 weeks -- these are distinct entities requiring different management approaches. Conjugated hyperbilirubinemia is never physiologic, and biliary atresia must be excluded urgently because Kasai portoenterostomy outcomes are critically time-dependent. TSB rather than TcB should guide treatment decisions near phototherapy thresholds, as transcutaneous measurements become less reliable at higher levels. Phototherapy failures should prompt investigation for ongoing hemolysis including reticulocyte count, direct antiglobulin test, peripheral smear, and G6PD assay. A follow-up bilirubin should always be checked after stopping phototherapy to detect rebound hyperbilirubinemia.
References
- Kemper AR, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859.
- Bhutani VK, et al. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia. Pediatrics. 1999;103(1):6-14.
- Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage — mechanisms and management approaches. N Engl J Med. 2013;369(21):2021-2030.
- Maisels MJ, et al. Hyperbilirubinemia in the newborn infant >=35 weeks' gestation: an update with clarifications. Pediatrics. 2009;124(4):1193-1198.
